Events

Info Day 2027 calls in Cluster 4
OCT
Wed
14
OCT
Thu
15

Starts in 3 days from now

Location

Online

Programmes
Digital, Industry & Space

This event aims to inform potential applicants about the funding opportunities of the Horizon Europe Cluster 4 - 'Digital, Industry and Space' Work Programme 2027.

Speakers from the European Commission will provide detailed insights into the call topics, evaluation and award processes. Attendees will have the opportunity to pose questions about new developments and learn how to draft successful proposals.

Draft agenda

Day 1 (14 October, 09:00-16:00) Sessions: Digital and Space topics

Day 2 (15 October, 09:00-16:30) Sessions: Industry topics and Horizontal Aspects

 

More information will follow later and is published on the official event website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.